NASDAQ:ARNA Arena Pharmaceuticals (ARNA) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$99.99▼$99.9950-Day Range$93.13▼$99.9952-Week Range$45.50▼$100.00Volume107 shsAverage Volume1.56 million shsMarket Capitalization$6.17 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Arena Pharmaceuticals alerts: Email Address Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. About Arena Pharmaceuticals Stock (NASDAQ:ARNA)Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.Read More Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. ARNA Stock News HeadlinesAugust 31, 2023 | uk.investing.comArwana Citramulia Tbk (ARNA)August 21, 2023 | foxnews.comMLS club places Bruce Arena on leave over probe into 'allegations of insensitive and inappropriate remarks'September 8, 2024 | Mode Mobile (Ad)Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.May 23, 2023 | bizjournals.comRNA startup launches with $300M, Merck partnershipMay 23, 2023 | seekingalpha.comLongboard Pharmaceuticals: Undervalued Arena Spin-Out Has 2 Data Catalysts Due In 2023May 6, 2023 | cnbc.comPfizer earnings and revenue top expectations despite Covid vaccine sales declineApril 25, 2023 | health.usnews.comArna L. DavidsonApril 12, 2023 | foxnews.comPortland, Maine, reopens basketball arena to migrantsSeptember 8, 2024 | Mode Mobile (Ad)Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.March 17, 2023 | forbes.comIs Pfizer Stock Undervalued At $40?February 9, 2023 | benzinga.comArna Marketing Group Continues Investing in State-of-the-art Canon Inkjet Technology to Deliver "The Arna Advantage"February 8, 2023 | finance.yahoo.comArna Marketing Group Continues Investing in State-of-the-art Canon Inkjet Technology to Deliver “The Arna Advantage”February 6, 2023 | msn.comA DNA protein may be responsible for causing cancerous ‘stress balls’ in the body: U of S researchAugust 23, 2022 | thestreet.comObesity Drugs: The Road to PerditionAugust 9, 2022 | baystreet.caPfizer to Buy Global Blood TherapeuticsAugust 4, 2022 | forbes.comShould You Buy Pfizer Stock After An Upbeat Q2?June 29, 2022 | forbes.comShould You Buy, Sell, Or Hold Pfizer Stock At $52?May 3, 2022 | theglobeandmail.com7 Biotech Stocks With Key Catalysts in MarchSee More Headlines Receive ARNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ARNA CUSIP04004710 CIK1080709 Webwww.arenapharm.com Phone(858) 453-7200Fax858-453-7210Employees448Year Founded1977Profitability EPS (Most Recent Fiscal Year)($10.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-616,430,000.00 Net MarginsN/A Pretax Margin-1,141,542.63% Return on Equity-69.83% Return on Assets-62.35% Debt Debt-to-Equity Ratio0.05 Current Ratio8.59 Quick Ratio8.59 Sales & Book Value Annual Sales$50,000.00 Price / Sales123,305.67 Cash FlowN/A Price / Cash FlowN/A Book Value$10.94 per share Price / Book9.14Miscellaneous Outstanding Shares61,659,000Free Float60,173,000Market Cap$6.17 billion OptionableOptionable Beta0.55 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesMr. Amit D. Munshi M.B.A. (Age 54)Pres & CEO Comp: $1.22MMs. Laurie D. Stelzer (Age 54)Exec. VP & CFO Comp: $630.76kMr. Vincent E. Aurentz (Age 54)Exec. VP & Chief Bus. Officer Comp: $692.82kDr. Christopher H. Cabell FACCM.D., MHS, AdvisorMr. Robert Lisicki (Age 54)Exec. VP & Chief Commercial Officer Comp: $686.63kDr. Douglas A. Bakan Ph.D.Exec. VP of Technical OperationsDr. Lamine Mbow Ph.D.Sr. VP & Chief Scientific OfficerMegan E. KnightDirector of Investor RelationsPatrick MalloyVP of Investor Relations & Corp. CommunicationsMr. Michael E. Paolucci (Age 62)Exec. VP of HR More ExecutivesKey CompetitorsApellis PharmaceuticalsNASDAQ:APLSChemoCentryxNASDAQ:CCXITG TherapeuticsNASDAQ:TGTXPrincipia BiopharmaNASDAQ:PRNBPTC TherapeuticsNASDAQ:PTCTView All Competitors ARNA Stock Analysis - Frequently Asked Questions How were Arena Pharmaceuticals' earnings last quarter? Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($3.21) EPS for the quarter, missing analysts' consensus estimates of ($2.53) by $0.68. When did Arena Pharmaceuticals' stock split? Arena Pharmaceuticals shares reverse split before market open on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 16th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Amit Munshi's approval rating as Arena Pharmaceuticals' CEO? 16 employees have rated Arena Pharmaceuticals Chief Executive Officer Amit Munshi on Glassdoor.com. Amit Munshi has an approval rating of 66% among the company's employees. What other stocks do shareholders of Arena Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Cytokinetics (CYTK), Micron Technology (MU), NVIDIA (NVDA) and Novavax (NVAX). This page (NASDAQ:ARNA) was last updated on 9/8/2024 by MarketBeat.com Staff From Our PartnersLast Call for Crypto Summit (RSVP FREE)The Dow recently shed nearly 1,000 points in a single day… Big tech stocks are getting slaughtered… And ...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredExposed: 3 CENT Crypto to Explode September 23rd?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arena Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arena Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.